Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
The University Health Network (UHN)'s spinout company AVROBIO recently raised more than US $100 million in an initial public offering (IPO) on the NASDAQ stock exchange. Less than one month after the announcement, the company has a market cap of greater than US $651 million.
The company, which was founded based on the work of UHN researchers Drs.
Christopher Paige (Senior Scientist) and Jeffrey Medin (now at the Medical College of Wisconsin), leverages cell and gene therapy platforms for cancer and rare diseases.
Specifically, AVROBIO is a clinical stage company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases in a single dose.
"Researchers have made rapid progress in the ability to alter gene expression patterns in cells and to use those modified cells to influence the course of disease," says Dr. Paige. "These findings are opening up new therapeutic approaches across a wide spectrum of unmet health needs."
"The founding of AVROBIO and now its IPO launch are excellent examples of how investing in basic science, translational and clinical research can get these much needed innovations to patients in the shortest time possible," explains Dr. Brad Wouters, Executive Vice President, Science and Research at UHN.
AVROBIO's IPO was well received by the investment community with significant participation by high quality institutional investors. The IPO follows several previous rounds of financing—resulting in over US $90 million invested, including a US $60 million Series B raise.
"AVROBIO's success demonstrates the strength of Toronto's research ecosystem and our ability to discover, develop and present commercially interesting research that attracts top investors and management teams," says Dr. John Reid, Director of UHN's Technology Development and Commercialization (TDC) Office.
Adds Mark Taylor from TDC, who worked closely with the company throughout the process, "We're proud to have helped advance AVROBIO from start-up incubation to IPO in approximately three years—a remarkable commercial feat."
AVROBIO is trading under the NASDAQ ticker symbol "AVRO".